Sign in

Sudan Loganison

Managing Director and equity research analyst at Stephens

Sudan Loganathan, PhD, is a Managing Director and equity research analyst at Stephens, specializing in the Biotechnology sector with a primary focus on oncology, immunology, and rare diseases. He covers a range of innovative biotech companies, leveraging his scientific background to provide detailed research and actionable investment insights, though specific performance metrics and company rankings have not been publicly disclosed. Loganathan began his equity research career with associate roles at RBC Capital Markets, H.C. Wainwright, and Cantor Fitzgerald, before joining Stephens in May 2023 as a senior analyst. He holds a B.S. in Biomedical Sciences from Murray State University and a Ph.D. in Neuroscience, Cancer Biology, and Pharmacology from Meharry Medical College and Vanderbilt University Medical Center, further supporting his credentials in financial analysis of life sciences firms.

Sudan Loganison's questions to EXELIXIS (EXEL) leadership

Question · Q3 2025

Sudan Loganison asked whether a broad label for colorectal cancer, encompassing both ITT and non-liver metastases (NLM) subgroups, could be expected with the planned NDA submission by year-end 2025, or if a rolling submission would be necessary. He also asked if regulatory guidance influenced the decision to split the subgroups.

Answer

Dana Aftab, Executive Vice President of Research and Development, clarified that the company intends to file based on the positive results from the ITT population, which is the entire trial population, and expects this to provide the broadest label. She noted that the NLM subgroup is a second dual primary endpoint, and the filing will proceed based on the ITT data.

Ask follow-up questions

Fintool

Fintool can predict EXELIXIS logo EXEL's earnings beat/miss a week before the call